We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
11/9/2019 15:09 | A bit of a tick up. Is the share price on it's way towards that 148p placing price? I don't know, but fingers crossed! | papillon | |
11/9/2019 15:08 | And she's off toward £1.48 | waterloo01 | |
11/9/2019 08:55 | Wonderful, thank you....... | bazworth | |
11/9/2019 08:27 | Asit Biotech (ASIT.BR) Market cap €24 M / Cash €10 Million / Phase 3 readout in December for their immunotherapy treatment for grass pollen (€500 Million peak sales potential)Unknown stock = Potential 10+ BAGGER GEM ...........GLTA Successful Pollen Season Confirms ASIT biotech On Track for Phase III Results of gp-ASIT+™ in December 2019 hxxps://www.globenew | ih_116147 | |
10/9/2019 19:21 | I posted exactly the same yesterday, webpax. I bought just 710 shares at 104.8p yesterday. As I posted this has often been the case with AMYT that you can buy below the arbitrary mid price ever since it listed. | papillon | |
10/9/2019 14:47 | A lot of these trades marked as sells are actually buys. It's possible to buy in decent size under 105 yet it shows up as a sell. E.g. I bought 4770 at 104.8 yesterday but it showed as a sell. | webpax | |
10/9/2019 00:56 | Future value of CVRs are difficult to predict at this stage. If we firstly assume that the probability of EASE hitting the primary endpoint is 60-70%. Then, you would need to consider the chance of the FDA and EMA approving the product for the indication, based on the drug dossiers submitted. If we assume that the probability of FDA and EMA providing a positive opinion (based on positive EASE results) are 60% and 80%, respectively (purely speculative figures) then overall chance of getting approval could be anywhere between 36 to 42% (for FDA) and 48 to 56% (for EMA). However, CVR milestone has a much higher value for FDA approval vs EMA (30 million vs 15 million). Finally, the CVR based on sales revenue will be highly dependent on FDA approval. Without FDA approval, it will be difficult to achieve these sales figures, in my opinion. | diamondstar1 | |
09/9/2019 22:54 | What surprises me, diamondstar, is that most trades today are sells; mostly small, but a few larger. The sellers are obviously not interested in the CVR's, so will not benefit from any future upside from AP101, assuming that it successfully passes Phase III and passes the milestones it has been set. Anyone selling before the proposed 20th September will not receive the CVR's. Presumably the sellers don't believe the CVR's will have any future value. | papillon | |
09/9/2019 21:38 | Hope Greendragon is OK! His favourite crypto - Iota/Miota is now down to 0.20 cents. The last time we heard from him, it was hovering around 0.50 cents. And yet, some cryptocurrencies such as bitcoin are doing well. Regarding Amryt, I think the share price will move upwards once the acquisition of Aegerion is completed. Till then, there is still some element of uncertainty. | diamondstar1 | |
09/9/2019 21:33 | positivityNicholas 9 Sep '19 - 20:01 - 4812 of 4812 (Filtered) | papillon | |
09/9/2019 20:01 | Papillon why do you recite what we can all see and the info is readily available to everyone? You are such a boring self important totally uninteresting poster | positivitynicholas | |
09/9/2019 13:57 | Well someone has paid the full asking price of 110p, but only because they bought 50k of shares @ a cost of £55k. That buy trade was recorded @ 9:18:53 this morning. Hence it looks like small investors (like me) who spend a pittance get such a good deal! Someone sold the grand total of 4 shares at 10:10:24 this morning @ 102.22p per share for proceeds of £4.09 before any commission so perhaps my £750 is not such a pittance after all! In fact of the 12 trades so far today there have been the following tiny sells of 4, 83, 26 & 13 shares respectively, plus another sell of 168 shares. I thought I was a small investor, but those small amounts beggar belief. | papillon | |
05/9/2019 14:50 | Going to be interesting to see where these settle post reversal. 25th Sept if I'm reading it right | waterloo01 | |
05/9/2019 12:52 | There appears to be a big disconnect between the current AMYT share price and the proposed US$60m placing @ 148p scheduled for when the Aegerion takeover is concluded later this month. This 148p proposed placing price is approximately 40% higher than the current share price Something is not right. Either the current share price is undervalued by 40%, or the placing price is overvalued by 40%!! I can't see anyone, apart from the Aegerion bondholders, being prepared to pay 148p for new AMYT shares. Fortunately that US$60m placing @ 148p appears to be supported by those taking part in the placing. However I wonder where the AMYT share price will settle once the placing is out of the way. I suspect closer to the 40% lower current share price pending the proposed listing on Nasdaq. bwtfdik? | papillon | |
05/9/2019 10:59 | LOL, volsung. It is suspended in Dublin, but not London! :-) | papillon | |
05/9/2019 09:05 | Is this share still suspended? Not a lot of movement :) | volsung | |
04/9/2019 14:36 | So Ray Stafford (of Sudocrem fame) and AMYT's proposed new Chairman has forked out £826k on AMYT shares in the recent initial interim placing. Going by this year old article Ray Stafford isn't short of a few quid!! | papillon |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions